VX-745

VX-745 · EIP Pharma Inc

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for VX-745, covering 2018-04-03 to 2019-06-14. Get the full timeline:

Most recent: Clinical Trial Update: A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD) [Phase 2]

See pricing